JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

Fate Therapeutics Inc

Gesloten

SectorGezondheidszorg

1.33 -10.14

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.3

Max

1.49

Belangrijke statistieken

By Trading Economics

Inkomsten

3.6M

-34M

Verkoop

278K

1.9M

Winstmarge

-1,786.576

Werknemers

181

EBITDA

979K

-37M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+185.16% upside

Dividenden

By Dow Jones

Volgende Winsten

10 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

71M

179M

Vorige openingsprijs

11.47

Vorige sluitingsprijs

1.33

Nieuwssentiment

By Acuity

31%

69%

88 / 373 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Fate Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 okt 2025, 23:50 UTC

Populaire aandelen

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 okt 2025, 23:25 UTC

Winsten

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 okt 2025, 23:18 UTC

Winsten

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 okt 2025, 22:20 UTC

Winsten

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 okt 2025, 22:13 UTC

Winsten

Wal-Mart de Mexico Net Profit Falls in 3Q

28 okt 2025, 21:38 UTC

Winsten

Correction to Visa Sales Jump Article

28 okt 2025, 21:17 UTC

Winsten

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 okt 2025, 21:07 UTC

Winsten

Visa Sales Jump as Consumers Keep Spending -- Update

28 okt 2025, 21:02 UTC

Winsten

Mondelez Tempers Outlook as Costs Rise

28 okt 2025, 23:51 UTC

Marktinformatie

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 okt 2025, 23:42 UTC

Marktinformatie

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 okt 2025, 23:02 UTC

Winsten

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 okt 2025, 23:01 UTC

Winsten

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 okt 2025, 22:46 UTC

Winsten

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 okt 2025, 22:45 UTC

Winsten

SK Hynix 3Q Net KRW12.6T >000660.SE

28 okt 2025, 22:44 UTC

Winsten

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 okt 2025, 22:43 UTC

Winsten

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 okt 2025, 22:42 UTC

Winsten

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 okt 2025, 22:40 UTC

Winsten

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 okt 2025, 22:40 UTC

Winsten

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 okt 2025, 22:22 UTC

Winsten

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 okt 2025, 22:22 UTC

Winsten

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 okt 2025, 22:22 UTC

Winsten

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 okt 2025, 22:20 UTC

Winsten

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 okt 2025, 22:02 UTC

Winsten

Review & Preview: Earnings Extravaganza -- Barrons.com

28 okt 2025, 21:42 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

28 okt 2025, 21:42 UTC

Marktinformatie
Winsten

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 okt 2025, 21:20 UTC

Winsten

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 okt 2025, 21:19 UTC

Winsten

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 okt 2025, 21:18 UTC

Winsten

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Peer Vergelijking

Prijswijziging

Fate Therapeutics Inc Prognose

Koersdoel

By TipRanks

185.16% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.42 USD  185.16%

Hoogste 7 USD

Laagste 2 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fate Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

8 ratings

4

Buy

4

Hold

0

Sell

Technische score

By Trading Central

0.9101 / 1.14Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bullish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

88 / 373 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
help-icon Live chat